Gross Profit Comparison: Arrowhead Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated Trends

Pharmaceutical Giants' Profit Trends: Arrowhead vs. Ligand

__timestampArrowhead Pharmaceuticals, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 201417500055402000
Thursday, January 1, 201538200066107000
Friday, January 1, 2016158333103402000
Sunday, January 1, 201731407709135736000
Monday, January 1, 201816142321245116000
Tuesday, January 1, 2019168795577108935000
Wednesday, January 1, 202087992066156000000
Friday, January 1, 2021138287000214957000
Saturday, January 1, 2022232810000143418000
Sunday, January 1, 202324073500096265000
Monday, January 1, 20243551000
Loading chart...

Unveiling the hidden dimensions of data

Gross Profit Trends: Arrowhead vs. Ligand Pharmaceuticals

In the dynamic world of pharmaceuticals, understanding financial trends is crucial. This chart highlights the gross profit trajectories of Arrowhead Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Arrowhead Pharmaceuticals has shown a remarkable growth, with its gross profit surging by over 137,000% from 2014 to 2023. In contrast, Ligand Pharmaceuticals experienced a more fluctuating trend, peaking in 2018 with a gross profit of approximately 245 million, before declining to around 96 million in 2023.

Arrowhead's consistent upward trend, especially post-2017, reflects its strategic advancements and market positioning. Meanwhile, Ligand's volatility suggests a need for strategic recalibration. Notably, data for 2024 is incomplete, indicating potential shifts in the coming year. This analysis provides a snapshot of the competitive landscape, offering insights into the financial health and strategic directions of these pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025